SGLT2 inhibitors and nephrolithiasis risk in patients with type 2 diabetes: A cohort study and meta-analysis
Authors' conclusion
This study suggests that SGLT2is may provide benefits beyond glycemic control by reducing nephrolithiasis risk, offering an advantage when selecting glucose-lowering therapies for patients with T2D.
Study context
- Population
- Adults with T2D initiating SGLT2i, DPP-4i or GLP-1 RA, January 2015–December 2023, 64 U.S. healthcare organizations
- Comparison
- SGLT2i vs DPP-4i and SGLT2i vs GLP-1 RA
- Outcome
- Nephrolithiasis risk
- Follow-up
- Up to 5 years
Methodological detailsreal-world, TriNetX Analytics Network, 64 U.S. healthcare organizations, matched pairs
- Real-world
- TriNetX Analytics Network, 64 U.S. healthcare organizations
- Matched pairs
Pooled result
As reported in the abstract
Nephrolithiasis
Hazard ratio (95% CI)
SGLT2isvs DPP4is500,000 patients (250,000 pairs)
0.86(0.83–0.90)
SGLT2isvs GLP-1RAs482,284 patients (241,142 pairs)
0.90(0.86–0.94)
Further pooled results
Meta-analysis of this study plus four additional real-world studies
- Further supported the lower nephrolithiasis risk with SGLT2is
Original publication
SGLT2 inhibitors and nephrolithiasis risk in patients with type 2 diabetes: A cohort study and meta-analysis. Diabetes Res Clin Pract. Published 6 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →